Drugs / recombinant vaccinia-CEA(6D)-TRICOM vaccine
last change Mar 2015 re-read 2 minutes ago

recombinant vaccinia-CEA(6D)-TRICOM vaccine

Vaccine

Developed for
cancer of unknown primary site · female breast carcinoma · lung cancer
Investigated by
National Cancer Institute (NCI)

Trials 3 · a red edge is where a trial was stopped

200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00009958 Nov 2000 → Apr 2010 cancer of unknown primary site National Cancer Institute (NCI) Terminated No outcome recorded
Phase 21 trial
Phase 2 NCT00052351 Sep 2002 → Oct 2007 female breast carcinoma National Cancer Institute (NCI) Completed No outcome recorded
Phase not applicable1 trial
NCT00091039 Aug 2004 → Feb 2006 lung cancer National Cancer Institute (NCI) Completed No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00217373 Background Jun 2005 → Jan 2013 neoplasm National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT00088933 Background Jun 2004 → Nov 2007 non-small cell lung carcinoma, rectal carcinoma, small cell lung carcinoma National Cancer Institute (NCI) Terminated No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as recombinant vaccinia-CEA(6D)-TRICOM vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00052351
3

NCT00217373

NCT00091039

NCT00088933

Known as rV-CEA(6D)-TRICOM rV-CEA(6D)-TRICOM (recombinant vaccinia-CEA(6D)-B7.1/ICAM-1/LFA-3)” NCT00009958
Known as vaccinia-CEA-TRICOM vaccine “Patients receive vaccinia-CEA-TRICOM vaccine subcutaneously (SC) on day 0 and fowlpox-CEA-TRICOM (rF-CEA-TRICOM) vaccine SC on days 14, 29, 43, 57, 70, 91, and 112.” NCT00091039
Known as vCEA-TRI “OUTLINE: This is a dose-escalation study of fowlpox-CEA-TRICOM (fCEA-TRI) vaccine and vaccinia-CEA-TRICOM (vCEA-TRI) vaccine.” NCT00009958
Action Deplete “Vaccines may make the body build an immune response to kill tumor cells.” NCT00088933
Modality Vaccine “novel CEA-based vaccineNCT00009958
Route Other “Given intradermally” NCT00009958